Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
6.53
-0.35 (-5.09%)
At close: Mar 28, 2025, 4:00 PM
6.69
+0.16 (2.45%)
After-hours: Mar 28, 2025, 6:36 PM EDT
Atara Biotherapeutics Revenue
In the year 2024, Atara Biotherapeutics had annual revenue of $128.94M with 1,404.02% growth. Atara Biotherapeutics had revenue of $32.75M in the quarter ending December 31, 2024, with 670.30% growth.
Revenue (ttm)
$128.94M
Revenue Growth
+1,404.02%
P/S Ratio
0.38
Revenue / Employee
$842,745
Employees
153
Market Cap
38.26M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ATRA News
- 23 days ago - Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress - Business Wire
- 4 weeks ago - The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation - Accesswire
- 6 weeks ago - The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation - Accesswire
- 6 weeks ago - Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws - PRNewsWire
- 6 weeks ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 6 weeks ago - Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 7 weeks ago - Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation - Accesswire
- 7 weeks ago - Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire